Sen. Tina Smith Sells Off Shares of Insulet Corporation (NASDAQ:PODD)

Senator Tina Smith (Democratic-Minnesota) recently sold shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on May 10th, the Senator disclosed that they had sold between $100,001 and $250,000 in Insulet stock on April 29th.

Senator Tina Smith also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 4/29/2026.
• Sold $50,001 – $100,000 in shares of 3M (NYSE:MMM) on 3/31/2026.
• Sold $100,001 – $250,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 3/31/2026.

Insulet Stock Down 0.8%

NASDAQ:PODD traded down $1.22 during mid-day trading on Friday, hitting $147.46. The stock had a trading volume of 1,441,853 shares, compared to its average volume of 1,643,372. The stock has a 50-day simple moving average of $199.93 and a two-hundred day simple moving average of $256.98. The company has a market capitalization of $10.21 billion, a PE ratio of 34.29, a PEG ratio of 1.21 and a beta of 1.20. Insulet Corporation has a twelve month low of $145.59 and a twelve month high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23. The firm had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm’s revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts anticipate that Insulet Corporation will post 6.44 EPS for the current year.

Hedge Funds Weigh In On Insulet

Hedge funds have recently modified their holdings of the business. Larson Financial Group LLC grew its position in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Insulet during the fourth quarter worth approximately $26,000. DV Equities LLC purchased a new position in Insulet in the 4th quarter valued at $28,000. Elyxium Wealth LLC purchased a new position in Insulet in the 4th quarter valued at $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new position in Insulet in the 4th quarter valued at $29,000.

Insiders Place Their Bets

In other news, Director Michael R. Minogue acquired 2,030 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the transaction, the director directly owned 17,483 shares in the company, valued at approximately $4,304,839.09. This represents a 13.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 0.36% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Canaccord Genuity Group dropped their price target on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Piper Sandler dropped their price target on shares of Insulet from $360.00 to $210.00 in a research note on Wednesday, May 6th. The Goldman Sachs Group set a $237.00 price target on shares of Insulet in a research note on Thursday, May 7th. Truist Financial dropped their price target on shares of Insulet from $315.00 to $250.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Finally, TD Cowen lowered shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 price target on the stock. in a research note on Monday, January 26th. Nineteen research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $257.09.

About Senator Smith

Tina Smith (Democratic Party) is a member of the U.S. Senate from Minnesota. She assumed office on January 3, 2018. Her current term ends on January 3, 2027. Smith (Democratic Party) ran for re-election to the U.S. Senate to represent Minnesota. She won in the general election on November 3, 2020. Smith succeeded former Senator Al Franken (D). She assumed office on January 3, 2018. Smith won a full term in the special general election for the position on November 6, 2018. She defeated Karin Housley (R), Sarah Wellington (Legal Marijuana Now Party), and Jerry Trooien (Unaffiliated) to win the seat. She advanced to the general election after defeating five challengers in the special Democratic primary election on August 14, 2018. Smith previously served as the 48th lieutenant governor of Minnesota. She was elected to the position on a joint ticket with incumbent Governor Mark Dayton on November 4, 2014, and was sworn into office on January 5, 2015.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.